Cloud Banner

Medical Devices

Image

Global Adalimumab Biosimilar Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Upcoming Report
  • Jan 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Adalimumab Biosimilar Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - 24.4% Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 598.30 Million
Diagram Market Size (Forecast Year) USD 3431.48 Million
Diagram CAGR 24.4%

Global Adalimumab Biosimilar Market, By Product (Exemptia, Adalirel, Cipleumab, Others), Indication (Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Other Indications), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

Adalimumab Biosimilar Market

Adalimumab Biosimilar Market Analysis and Size

According to GLOBOCAN 2020, there will be 2,281,658 new cancer cases and nearly 612,390 deaths in the United States in 2020. Furthermore, key market participants predicted market growth over the forecast period through various strategic activities such as product launches, mergers, and acquisitions. For instance, in July 2021, the FDA approved Viatris Inc.'s (formerly Mylan Pharmaceuticals Inc.) SEMGLEE (insulin-glargine-yfgn), a biosimilar to LANTUS (insulin glargine).

Data Bridge Market Research analyses that the adalimumab biosimilar market which is USD 598.30 million in 2022, is expected to reach USD 3431.48 million by 2030, at a CAGR of 24.4% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Adalimumab Biosimilar Market Scope and Segmentation      

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product (Exemptia, Adalirel, Cipleumab, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Alfred E. Tiefenbacher (GmbH & Co. KG) (Germany), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Glenmark (India), Zydus Group (India), Torrent Pharmaceuticals Ltd. (India), Reliance Life Sciences (India), Emcure Pharmaceuticals Ltd (India), Cipla Inc. (India), Hetero (India), AET BioTech (Germany), Coherus Biosciences (U.S.), Fujifilm Kyowa Kirin Biologics Co. Ltd. (Japan), Momenta Pharmaceuticals (U.S.), Oncobiologics (U.S.), Pfizer Inc. (U.S.), Samsung Bioepsis (South Korea), Sandoz International GmbH (Switzerland)

Market Opportunities

  • Rising cancer cases

Market Definition

Adalimumab, a monoclonal antibody, is used to treat autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, among others. This medication helps to prevent future joint damage and maintain joint function by reducing joint swelling. As the global prevalence of arthritis rises, the market for adalimumab biosimilars is expected to grow during the forecast period.

Adalimumab Biosimilar Market Dynamics

Drivers

  • Rise in biologic drugs

Several blockbuster biologic drugs from major pharmaceutical companies, including Truvada, Chantix, Forteo, Ciprodex, Afinitor, and many others, will lose US exclusivity in 2020. Several existing biological drugs, such as Erbitux, Avastin, and Orencia, will have their patents expire in the coming decade, providing an opportunity for many innovator companies as well as generic manufacturers to offer services specifically tailored toward biosimilars. Furthermore, the cost-effective nature of biosimilars, rising acceptance and adoption by various stakeholders, the need for diversification in technology and business models, and the growing prevalence of chronic diseases are expected to drive the global biosimilar market.

Opportunities

  • Rising cancer cases

Cancer's growing burden and rising death toll necessitate the need for affordable treatment, boosting the growth of the biosimilar market. According to GLOBOCAN 2020, there will be 2,281,658 new cancer cases and nearly 612,390 deaths in the United States in 2020. Furthermore, key market participants predicted market growth during the forecast period through a variety of strategic activities such as product launches, mergers, and acquisitions. For instance, in July 2021, the FDA approved Viatris Inc.'s (formerly Mylan Pharmaceuticals Inc.) SEMGLEE (insulin-glargine-yfgn), a biosimilar to LANTUS (insulin glargine).

Restraints/Challenges

  • High cost

The high cost associated with biosimilars will obstruct the market's growth rate. However, the global adalimumab biosimilar market is hampered by a scarcity of skilled specialists. Furthermore, factors such as high temperature sensitivity, lack of efficacy and safety, and high manufacturing costs associated with generic drugs are expected to limit market growth between 2022 and 2030.

This adalimumab biosimilar market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the adalimumab biosimilar market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Adalimumab Biosimilar Market Scope

The adalimumab biosimilar market is segmented on the basis of product and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Exemptia
  • Adalirel
  • Cipleumab
  • Others

Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others

Adalimumab Biosimilar Market Regional Analysis/Insights

The adalimumab biosimilar market is analyzed and market size insights and trends are provided by country, product and distribution channel as referenced above.

The countries covered in the adalimumab biosimilar market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the adalimumab biosimilar market due to the proximity of multiple extensive experimentation laboratories.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because of the province's extensive commercial advancements and growing biotechnology corporations.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Adalimumab Biosimilar Market Share Analysis

The adalimumab biosimilar market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to adalimumab biosimilar market.

Some of the major players operating in the adalimumab biosimilar market are:

  • Alfred E. Tiefenbacher (GmbH & Co. KG) (Germany)
  • Amgen Inc. (U.S.)
  • Boehringer Ingelheim International GmbH (Germany)
  • Glenmark (India)
  • Zydus Group (India)
  • Torrent Pharmaceuticals Ltd. (India)
  • Reliance Life Sciences (India)
  • Emcure Pharmaceuticals Ltd (India)
  • Cipla Inc. (India)
  • Hetero (India)
  • AET BioTech (Germany)
  • Coherus Biosciences (U.S.)
  • Fujifilm Kyowa Kirin Biologics Co. Ltd. (Japan)
  • Momenta Pharmaceuticals (U.S.)
  • Oncobiologics (U.S.)
  • Pfizer Inc. (U.S.)
  • Samsung Bioepsis (South Korea)
  • Sandoz International GmbH (Switzerland)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The adalimumab biosimilar market size will be worth USD 3431.48 million by 2030.
The growth rate of the adalimumab biosimilar market is 24.4% in the forecast by 2030.
Major companies in the adalimumab biosimilar market are Alfred E. Tiefenbacher (GmbH & Co. KG) (Germany), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Glenmark (India), Zydus Group (India), Torrent Pharmaceuticals Ltd. (India), etc.
Product and distribution channel are the factors on which the adalimumab biosimilar market research is based.
Cost-effective nature of biosimilars, rising acceptance and adoption by various stakeholders, the need for diversification in technology and business models, and the growing prevalence of chronic diseases are the growth drivers of the adalimumab biosimilar market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials